Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

61.87USD
22 May 2018
Change (% chg)

$-0.24 (-0.39%)
Prev Close
$62.11
Open
$62.12
Day's High
$62.28
Day's Low
$61.87
Volume
124,780
Avg. Vol
1,828,037
52-wk High
$64.60
52-wk Low
$43.11

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $107,628.20
Shares Outstanding(Mil.): 1,753.19
Dividend: 0.28
Yield (%): 1.82

Financials

  ABT.N Industry Sector
P/E (TTM): 58.13 28.66 32.90
EPS (TTM): 1.06 -- --
ROI: 2.94 13.20 12.74
ROE: 5.90 14.95 14.64

BRIEF-Abbott's Investigational Tendyne Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

* ABBOTT'S INVESTIGATIONAL TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT DEMONSTRATES POSITIVE OUTCOMES AT 30 DAYS IN GLOBAL STUDY

6:13am EDT

BRIEF-5-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions

* FIVE-YEAR STUDY DATA CONFIRM POSITIVE OUTCOMES FOR PATIENTS WHEN ABBOTT DIAGNOSTIC TOOL WAS USED TO GUIDE HEART STENTING DECISIONS Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

* ABBOTT EXPANDS CARDIAC ARRHYTHMIAS PORTFOLIO WITH FDA CLEARANCE OF ADVANCED MAPPING CATHETER

May 03 2018

UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade

* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)

May 03 2018

BRIEF-Abbott's Xience Sierra Heart Stent Receives National Reimbursement In Japan

* ABBOTT'S XIENCE SIERRA™ HEART STENT RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PEOPLE WITH CORONARY ARTERY DISEASE Source text for Eikon: Further company coverage:

May 02 2018

BRIEF-Abbott Laboratories Says Shareholders Rejected Proposal Requesting Board Of Directors Adopt Policy That Board Chairman Be Independent Director

* ABBOTT LABORATORIES SAYS SHAREHOLDERS REJECTED PROPOSAL REQUESTING CO'S BOARD OF DIRECTORS ADOPT POLICY THAT BOARD CHAIRMAN BE INDEPENDENT DIRECTOR Source text: (https://bit.ly/2KqCwQY) Further company coverage:

Apr 30 2018

BRIEF-Abbott Laboratories - Co, Sanquin Sign Multiple-Year Contract For Supply Of Primary Serological Equipment And Consumables

* ABBOTT LABORATORIES - CO, SANQUIN SIGN MULTIPLE-YEAR CONTRACT FOR SUPPLY OF PRIMARY SEROLOGICAL EQUIPMENT AND CONSUMABLES Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 23 2018

Abbott sticks to earlier forecasts, disappoints investors

Abbott Laboratories' just beat expectations for first quarter profits and revenue on Wednesday but stuck to a full-year profit forecast some investors had expected would be raised, sending the healthcare company's shares lower.

Apr 18 2018

UPDATE 3-Abbott sticks to earlier forecasts, disappoints investors

* Analysts cite disappointment on whisper numbers among investors

Apr 18 2018

BRIEF-Abbott Q1 GAAP Earnings Per Share $0.23 From Continuing Operations

* Q1 GAAP EARNINGS PER SHARE $0.23 FROM CONTINUING OPERATIONS

Apr 18 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $123.52 -0.20
Pfizer Inc. (PFE.N) $35.89 +0.09
Novartis AG (NOVN.S) CHF76.60 -0.40
Merck & Co., Inc. (MRK.N) $58.81 +0.24
Sanofi SA (SASY.PA) €66.30 +0.12
AstraZeneca plc (AZN.L) 5,443.00 +26.00
GlaxoSmithKline plc (GSK.L) 1,509.80 +13.00
Eli Lilly And Co (LLY.N) $82.56 +0.73
Amgen, Inc. (AMGN.OQ) $177.03 +0.56
Boston Scientific Corporation (BSX.N) $30.57 -0.08

Earnings vs. Estimates